Match!

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study

Published on May 20, 2017in Journal of Clinical Oncology28.25
· DOI :10.1200/PO.17.00002
Apostolia Maria Tsimberidou50
Estimated H-index: 50
(University of Texas MD Anderson Cancer Center),
David K. Hong54
Estimated H-index: 54
(University of Texas MD Anderson Cancer Center)
+ 15 AuthorsRazelle Kurzrock99
Estimated H-index: 99
(UCSD: University of California, San Diego)
Abstract
PurposeGenomic profiling is increasingly used in the management of cancer. We have previously reported preliminary results of our precision medicine program. Here, we present response and survival outcomes for 637 additional patients who were referred for phase I trials and were treated with matched targeted therapy (MTT) when available.Patients and MethodsPatients with advanced cancer who underwent tumor genomic analyses were treated with MTT when available.ResultsOverall, 1,179 (82.1%) of 1,436 patients had one or more alterations (median age, 59.7 years; men, 41.2%); 637 had one or more actionable aberrations and were treated with MTT (n = 390) or non-MTT (n = 247). Patients who were treated with MTT had higher rates of complete and partial response (11% v 5%; P = .0099), longer failure-free survival (FFS; 3.4 v 2.9 months; P = .0015), and longer overall survival (OS; 8.4 v 7.3 months; P = .041) than did unmatched patients. Two-month landmark analyses showed that, for MTT patients, FFS for responders v...
  • References (24)
  • Citations (17)
References24
Newest
#1Jennifer J. Wheler (University of Texas MD Anderson Cancer Center)H-Index: 32
#2Filip JankuH-Index: 41
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
#1Jennifer J. Wheler (University of Texas MD Anderson Cancer Center)H-Index: 32
#2Filip JankuH-Index: 41
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Barbara A. Parker (UCSD: University of California, San Diego)H-Index: 52
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 12 authors...
#1K. Koehler (OSU: Ohio State University)H-Index: 1
#2David A. Liebner (OSU: Ohio State University)H-Index: 12
Last.J. L. Chen (OSU: Ohio State University)H-Index: 1
view all 3 authors...
#1Apostolia Maria Tsimberidou (University of Texas MD Anderson Cancer Center)H-Index: 50
#2Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Gregory A. Daniels (UCSD: University of California, San Diego)H-Index: 24
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Vladimir LazarH-Index: 46
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
#1Sandip Pravin Patel (UCSD: University of California, San Diego)H-Index: 16
#2Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
Cited By17
Newest
#1Jason K. Sicklick (UCSD: University of California, San Diego)H-Index: 25
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
#1Jordi Rodon (University of Texas MD Anderson Cancer Center)H-Index: 23
#2Jean-Charles SoriaH-Index: 79
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 25 authors...
#1R Galot (UCL: Université catholique de Louvain)H-Index: 1
#2C. Le Tourneau (Curie Institute)H-Index: 15
Last.J P Machiels (UCL: Université catholique de Louvain)H-Index: 2
view all 16 authors...
View next paperMolecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.